-
Uncategorized1 month agoSTAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
The Food and Drug Administration on Thursday approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new...
-
Uncategorized1 month ago
BMS welcomes new multiple myeloma drug as generics batter current portfolio
The FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year,...
-
Uncategorized1 month ago
Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study
Sponsors of the pivotal study behind Amgen’s rare disease drug Tavneos saw unblinded findings for the drug and re-adjudicated data from nine patients to make the...
-
Uncategorized1 month agoBiotech initiatives pick up as more regions race to become hubs
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next. Read More
-
Uncategorized1 month agoTwo years after rules overhaul, have methadone clinics really changed?
Methadone clinics are finally getting their report card. In 2024, with the specialized addiction treatment providers facing backlash from patient groups and scrutiny from lawmakers, the...
-
Uncategorized1 month ago
Nascent US psychedelic therapy opportunity attracts overseas manufacturers
Companies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market.
-
Uncategorized1 month agoThermo and Michael J. Fox Foundation Collaborate to Advance Proteomics-Enabled Parkinson’s Therapy
Thermo Fisher Scientific completed an Olink Explore HT proteomic analysis of approximately 5,500 research samples from the Michael J. Fox Foundation’s (MJFF) landmark study, the Parkinson’s...
-
Uncategorized1 month ago
Dynamism and evolvability in nucleic acid enzymes
Post Content
-
Uncategorized1 month agoSTAT+: Commure terminates payments under its customer referral programs tied to AI products
Commure, a $7 billion health software company that sells artificial intelligence tools to medical clinics, has terminated a program through which it was paying parties for...
-
Uncategorized1 month agoAdvancing Microbial-Derived Biologics from Scale-Up to Commercial Production
Register Now Sam Zhang, PhD Vice President, Head of Microbial and Viral Platforms (MVP)WuXi Biologics View Bio Panelist Sam Zhang, PhD Sam Zhang, PhD, has more...
FDA clears first generic radioligand drug; Sionna turns to layoffs
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Ensuring safety and accountability in China’s biomedical translation system
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
